Mobile

Open, randomized, controlled, multicenter phase III study comparing cisplatin / vinoelbine plus cetuximab versus cisplatin / vinorelbine as first-line treament for patients with EGFR-expessing advance...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001105-96

Open, randomized, controlled, multicenter phase III study comparing cisplatin / vinoelbine plus cetuximab versus cisplatin / vinorelbine as first-line treament for patients with EGFR-expessing advanced NSCLC

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To show superiority in terms of overall survival time of patients receiving platinum-based chemotherapy plus cetuximab as first-line treatment compared with patients receiving the same chemotherapy alone.

Critère d'inclusion

  • Epidermal growth factor receptor-expressing advanced non-small cell lung cancer

Liens